Skip Navigation



JAC Advance Access published online on October 23, 2009
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkp390
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Badali, H.
Right arrow Articles by Meis, J. F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Badali, H.
Right arrow Articles by Meis, J. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letter

In vitro activities of antifungal drugs against Rhinocladiella mackenziei, an agent of fatal brain infection

Hamid Badali1,2,3, G. Sybren de Hoog1,2, Ilse Curfs-Breuker4 and Jacques F. Meis4,*

1 CBS-KNAW Fungal Biodiversity Centre, Utrecht, The Netherlands 2 Institute of Biodiversity and Ecosystem Dynamics, University of Amsterdam, Amsterdam, The Netherlands 3 Department of Medical Mycology and Parasitology, School of Medicine/Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran 4 Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands

* Corresponding author. Tel: +31-24-3657514; Fax: +31-24-3657516; E-mail: j.meis@cwz.nl

Key Words: cerebral fungal infection , in vitro susceptibility , Ramichloridium , isavuconazole , posaconazole

The first 10% of the full text of this article appears below.

Sir,

Cerebral phaeohyphomycosis is a rare disease with a mortality of up to 70% despite combinations of surgical and antifungal therapy.1 This infection is predominantly caused by Exophiala dermatitidis, Cladophialophora bantiana and Rhinocladiella mackenziei (order Chaetothyriales, family Herpotrichiellaceae), although organisms from other orders including Pleosporales, Sordariales, Xylariales and Helotiales can also cause infection. Rhinocladiella is a genus of black yeast-like fungi and can cause human infections ranging from mild cutaneous lesions to fatal brain infections.2 R. mackenziei (formerly Ramichloridium mackenziei) is an extremely neurotropic fungus, and infections that invade the CNS cause death in most instances.1,2 The infection is restricted largely . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?